1. Phylogeny  
MAP3K13, commonly referred to as LZK (Leucine zipper‐bearing kinase), is a member of the mitogen‐activated protein kinase kinase kinase (MAP3K) family that functions within the broader TKL (tyrosine kinase–like) subgroup. LZK belongs to the mixed lineage kinase (MLK) set of kinases and is closely related to other dual leucine zipper–bearing kinases such as DLK (MAP3K12). Comparative genomic analyses have positioned MAP3K13 among evolutionarily conserved kinases, with clear orthologs in vertebrates and a close relationship with other MLK family members observed in higher eukaryotes (jin2019multitaskingdualleucine pages 3-4, gallo2002mixedlineagekinasecontrol pages 2-3). Detailed phylogenetic reconstructions, based on refined ortholog inferences within the MAPK signaling network, indicate that MAP3K13 clusters with kinases that have undergone vertebrate‐specific expansion after their origin early in eukaryotic evolution (huang2025refinedphylogeneticortholog pages 1-12). The evolutionary trajectory of MAP3K13 reveals that it emerged via the same whole genome duplication events that generated closely related paralogs, and its specialized sequence features, such as the presence of leucine zipper motifs, offer a way to distinguish its function from other MAP3Ks. Together, these observations support its assignment to a core kinase group that comprises a key component in signal transduction related to stress and developmental stimuli (jin2019multitaskingdualleucine pages 3-4, gallo2002mixedlineagekinasecontrol pages 2-3).

2. Reaction Catalyzed  
MAP3K13 catalyzes a classical phosphorylation reaction typical of serine/threonine kinases. In biochemical terms, the reaction involves the binding of ATP and the specific MAP kinase kinase (MAP2K) substrate – notably MAP2K7 – to the catalytic domain of LZK. The enzyme then mediates the transfer of the gamma (γ)‐phosphate group from ATP to a hydroxyl group on serine/threonine residues present in the activation loop of its substrate. This reaction can be summarized as follows:  
  ATP + [MAP2K substrate]–OH → ADP + [MAP2K substrate]–O–P + H⁺  
Such phosphorylation events are the initial step in a sequential signaling cascade that ultimately leads to JUN N-terminal kinase (JNK) pathway activation (ha2019phosphorylationdynamicsof pages 3-6, gallo2002mixedlineagekinasecontrol pages 3-4).

3. Cofactor Requirements  
The catalytic activity of MAP3K13, like most kinases, necessitates the presence of specific cofactors for efficient catalysis. The enzyme requires ATP to serve as the phosphate donor during the phosphorylation reaction, and the reaction is typically carried out in the presence of magnesium ions (Mg²⁺) which stabilize the ATP molecule and facilitate proper substrate orientation within the active site. This requirement for Mg²⁺ is common among serine/threonine kinases and is critical for optimal enzyme activity (ha2019phosphorylationdynamicsof pages 3-6).

4. Substrate Specificity  
MAP3K13 exhibits a defined substrate specificity that is central to its role in signal transduction. It preferentially phosphorylates members of the MAP kinase kinase family, with a marked specificity for MAP2K7. The phosphorylation event occurs at conserved serine/threonine residues located within the activation loop of MAP2K7, which is a critical modification that leads to the subsequent engagement and activation of JNK isoforms. The substrate recognition is mediated not only by structural compatibility between the kinase domain of MAP3K13 and the MAP2K substrate but also by auxiliary protein–protein interactions. Scaffold proteins such as JNK-interacting protein 1 (JIP1) help recruit MAP3K13 to its substrate, thereby enhancing the efficiency and selectivity of the phosphorylation reaction (ha2019phosphorylationdynamicsof pages 3-6, park2019mkk7theessential pages 12-13, margutti2007aremapkinases pages 6-8). Although an explicit consensus phosphorylation motif for MAP3K13 has not been explicity defined in the primary literature, its substrate specificity is functionally evidenced by selective activation of MAP2K7 leading to downstream JNK signaling.

5. Structure  
The structural organization of MAP3K13 is defined by a central catalytic domain characteristic of serine/threonine protein kinases, flanked by regulatory regions that include leucine zipper motifs. The catalytic kinase domain harbors all the conserved features necessary for catalytic activity: an activation loop that becomes phosphorylated, a catalytic loop containing the highly conserved DFG (Asp–Phe–Gly) motif, and a C-helix that forms part of the hydrophobic regulatory spine. Unique to MAP3K13, and distinct from some of its paralogs, is the presence of one or more leucine zipper motifs that facilitate homodimerization; dimer formation is crucial for its activation and for the assembly of higher-order signaling complexes (jin2019multitaskingdualleucine pages 3-4, gallo2002mixedlineagekinasecontrol pages 3-4). In addition to the leucine zippers, structural analysis and predictive modeling (including data from homologous kinases and AlphaFold-generated models) suggest a unique hexapeptide motif (SDGLSD) that appears to be distinctive for MAP3K13. This motif may contribute to the specific interaction interfaces required for binding to scaffold proteins such as JIP1 and for modulating substrate selection. Overall, the three-dimensional architecture of MAP3K13 is typical for MAP3K enzymes yet incorporates distinct structural elements that underpin its specialized biological functions.

6. Regulation  
The regulation of MAP3K13 is achieved through multiple mechanisms that ensure the appropriate spatiotemporal control of its kinase activity. Activation of MAP3K13 is generally elicited by extrinsic stress signals and pro-inflammatory cytokines, which initiate a cascade leading to its phosphorylation. Post-translational modification by phosphorylation within its activation loop is a critical determinant in the transition from an inactive to an active conformation. In parallel, interaction with scaffold proteins like JNK-interacting protein 1 (JIP1) is essential for the organization of the kinase into a signaling complex, thereby enhancing substrate specificity and catalytic efficiency. In this context, the formation of a ternary complex involving MAP3K13, its substrate MAP2K7, and JIP1 acts as a molecular switch that amplifies the JNK signaling cascade. Negative regulation is mediated by dual-specificity phosphatases (DUSPs), which dephosphorylate components of the MAP kinase cascade to attenuate signal transmission. This balance between kinase activation and phosphatase-mediated deactivation maintains signal fidelity and prevents aberrant cellular responses (ha2019phosphorylationdynamicsof pages 3-6, park2019mkk7theessential pages 2-4, bensen2021newtherapeuticopportunities pages 8-10, rana2013mixedlineagekinasecjun pages 2-3).

7. Function  
MAP3K13 serves as a pivotal signaling node within the cellular stress response. Its primary function is to initiate the activation of the JUN N-terminal kinase (JNK) pathway by phosphorylating MAP2K7. The ensuing phosphorylation cascade results in the activation of JNK, which then phosphorylates a range of transcription factors, including c-Jun, to modulate gene expression programs that govern apoptosis, cell survival, differentiation, and inflammatory responses. Beyond its role in JNK pathway activation, MAP3K13 also collaborates with peroxiredoxin 3 (PRDX3) to regulate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. In this capacity, MAP3K13 participates in the activation of the IκB kinase complex, particularly by engaging the IKBKB-containing complex, which phosphorylates the inhibitors of NF-κB, thereby promoting NF-κB nuclear translocation and transcriptional activity. Expression studies indicate that MAP3K13 is widely expressed in various tissues, where its activity contributes to both basal and stress-induced cellular responses. The dual role of MAP3K13 in modulating both the JNK and NF-κB pathways positions it as a critical mediator in cell fate decisions, especially in contexts involving inflammatory signaling and stress-induced apoptosis (ha2019phosphorylationdynamicsof pages 3-6, park2019mkk7theessential pages 2-4, bensen2021newtherapeuticopportunities pages 8-10, margutti2007aremapkinases pages 6-8).

8. Other Comments  
Experimental efforts to modulate the activity of kinases within the MAPK cascade have led to the development of various small-molecule inhibitors aimed at components of the JNK pathway. Although selective inhibitors specifically targeting MAP3K13 remain less extensively characterized than those for downstream kinases, research on related dual leucine zipper kinases provides a framework for inhibitor development. The dysregulation of MAP3K13 has been implicated in pathological contexts such as inflammatory disorders and certain cancers, including head and neck squamous cell carcinoma, in which aberrant JNK and NF-κB signaling may contribute to uncontrolled cell proliferation and survival. These disease associations highlight the potential therapeutic benefits of selectively modulating MAP3K13 activity. Inhibitor development remains an active area of investigation, with the prospect of identifying compounds that can precisely target the ATP-binding pocket or disrupt critical protein–protein interfaces essential for MAP3K13 dimerization and scaffold recruitment (bensen2021newtherapeuticopportunities pages 8-10, margutti2007aremapkinases pages 6-8, rattanasinchai2016mlk3signalingin pages 3-5).

9. References  
1. ha2019phosphorylationdynamicsof pages 3-6 – Jain Ha, Eunjeong Kang, Jihye Seo, and Sayeon Cho. “Phosphorylation dynamics of JNK signaling: effects of dual-specificity phosphatases (DUSPs) on the JNK pathway.” International Journal of Molecular Sciences, Dec 2019. doi:10.3390/ijms20246157.  
2. huang2025refinedphylogeneticortholog pages 1-12 – EJ Huang, Jeeun Parksong, Amy F. Peterson, Fernando Torres, Sergi Regot, and Gabriel S. Bever. “Refined phylogenetic ortholog inference reveals coevolutionary expansion of the MAPK signaling network through finetuning of pathway specificity.” Journal of Molecular Evolution, May 2025. doi:10.1007/s00239-025-10254-8.  
3. jin2019multitaskingdualleucine pages 3-4 – Yishi Jin and Binhai Zheng. “Multitasking: dual leucine zipper–bearing kinases in neuronal development and stress management.” Annual Review of Cell and Developmental Biology, 35:501-521, Oct 2019. doi:10.1146/annurev-cellbio-100617-062644.  
4. gallo2002mixedlineagekinasecontrol pages 2-3 – Kathleen A. Gallo and Gary L. Johnson. “Mixed-lineage kinase control of JNK and p38 MAPK pathways.” Nature Reviews Molecular Cell Biology, 3:663-672, Sep 2002. doi:10.1038/nrm906.  
5. gallo2002mixedlineagekinasecontrol pages 3-4 – Kathleen A. Gallo and Gary L. Johnson. “Mixed-lineage kinase control of JNK and p38 MAPK pathways.” Nature Reviews Molecular Cell Biology, 3:663-672, Sep 2002. doi:10.1038/nrm906.  
6. burkhard2009developmentofextracellular pages 2-3 – Kimberly Burkhard, Sarice Smith, Rahul Deshmukh, Alexander MacKerell Jr., and Paul Shapiro. “Development of extracellular signal-regulated kinase inhibitors.” Current Topics in Medicinal Chemistry, 9:678-689, May 2009. doi:10.2174/156802609789044416.  
7. bensen2021newtherapeuticopportunities pages 8-10 – Ryan Bensen and John Brognard. “New therapeutic opportunities for the treatment of squamous cell carcinomas: a focus on novel driver kinases.” International Journal of Molecular Sciences, 22:2831, Mar 2021. doi:10.3390/ijms22062831.  
8. margutti2007aremapkinases pages 6-8 – Simona Margutti and Stefan A. Laufer. “Are MAP kinases drug targets? Yes, but difficult ones.” ChemMedChem, Aug 2007. doi:10.1002/cmdc.200600271.  
9. park2019mkk7theessential pages 2-4 – Jae Gwang Park, Nur Aziz, and Jae Youl Cho. “MKK7, the essential regulator of JNK signaling involved in cancer cell survival: a newly emerging anticancer therapeutic target.” Therapeutic Advances in Medical Oncology, Sep 2019. doi:10.1177/1758835919875574.  
10. rana2013mixedlineagekinasecjun pages 2-3 – A. Rana, B. Rana, Rajakishore Mishra, Gautam Sondarva, Velusamy Rangasamy, Subhasis Das, N. Viswakarma, and A. Kanthasamy. “Mixed lineage kinase-C-Jun N-terminal kinase axis: a potential therapeutic target in cancer.” Genes & Cancer, 4:334-341, Apr 2013. doi:10.1177/1947601913485415.  
11. rattanasinchai2016mlk3signalingin pages 3-5 – Chotirat Rattanasinchai and Kathleen Gallo. “MLK3 signaling in cancer invasion.” Cancers, 8:51, May 2016. doi:10.3390/cancers8050051.  
12. cuevas2007roleofmitogenactivated pages 5-7 – B. Cuevas, A. Abell, and G. Johnson. “Role of mitogen-activated protein kinase kinase kinases in signal integration.” Oncogene, 26:3159-3171, May 2007. doi:10.1038/sj.onc.1210409.

References

1. (ha2019phosphorylationdynamicsof pages 3-6): Jain Ha, Eunjeong Kang, Jihye Seo, and Sayeon Cho. Phosphorylation dynamics of jnk signaling: effects of dual-specificity phosphatases (dusps) on the jnk pathway. International Journal of Molecular Sciences, Dec 2019. URL: https://doi.org/10.3390/ijms20246157, doi:10.3390/ijms20246157. This article has 75 citations and is from a peer-reviewed journal.

2. (huang2025refinedphylogeneticortholog pages 1-12): EJ Huang, Jeeun Parksong, Amy F. Peterson, Fernando Torres, Sergi Regot, and Gabriel S. Bever. Refined phylogenetic ortholog inference reveals coevolutionary expansion of the mapk signaling network through finetuning of pathway specificity. Journal of Molecular Evolution, May 2025. URL: https://doi.org/10.1007/s00239-025-10254-8, doi:10.1007/s00239-025-10254-8. This article has 0 citations and is from a peer-reviewed journal.

3. (jin2019multitaskingdualleucine pages 3-4): Yishi Jin and Binhai Zheng. Multitasking: dual leucine zipper–bearing kinases in neuronal development and stress management. Annual Review of Cell and Developmental Biology, 35:501-521, Oct 2019. URL: https://doi.org/10.1146/annurev-cellbio-100617-062644, doi:10.1146/annurev-cellbio-100617-062644. This article has 42 citations and is from a domain leading peer-reviewed journal.

4. (burkhard2009developmentofextracellular pages 2-3): Kimberly Burkhard, Sarice Smith, Rahul Deshmukh, Alexander MacKerell Jr., and Paul Shapiro. Development of extracellular signal-regulated kinase inhibitors. Current Topics in Medicinal Chemistry, 9:678-689, May 2009. URL: https://doi.org/10.2174/156802609789044416, doi:10.2174/156802609789044416. This article has 58 citations and is from a peer-reviewed journal.

5. (gallo2002mixedlineagekinasecontrol pages 2-3): Kathleen A. Gallo and Gary L. Johnson. Mixed-lineage kinase control of jnk and p38 mapk pathways. Nature Reviews Molecular Cell Biology, 3:663-672, Sep 2002. URL: https://doi.org/10.1038/nrm906, doi:10.1038/nrm906. This article has 699 citations and is from a domain leading peer-reviewed journal.

6. (bensen2021newtherapeuticopportunities pages 8-10): Ryan Bensen and John Brognard. New therapeutic opportunities for the treatment of squamous cell carcinomas: a focus on novel driver kinases. International Journal of Molecular Sciences, 22:2831, Mar 2021. URL: https://doi.org/10.3390/ijms22062831, doi:10.3390/ijms22062831. This article has 11 citations and is from a peer-reviewed journal.

7. (gallo2002mixedlineagekinasecontrol pages 3-4): Kathleen A. Gallo and Gary L. Johnson. Mixed-lineage kinase control of jnk and p38 mapk pathways. Nature Reviews Molecular Cell Biology, 3:663-672, Sep 2002. URL: https://doi.org/10.1038/nrm906, doi:10.1038/nrm906. This article has 699 citations and is from a domain leading peer-reviewed journal.

8. (margutti2007aremapkinases pages 6-8): Simona Margutti and Stefan A. Laufer. Are map kinases drug targets? yes, but difficult ones. ChemMedChem, Aug 2007. URL: https://doi.org/10.1002/cmdc.200600271, doi:10.1002/cmdc.200600271. This article has 62 citations and is from a peer-reviewed journal.

9. (park2019mkk7theessential pages 12-13): Jae Gwang Park, Nur Aziz, and Jae Youl Cho. Mkk7, the essential regulator of jnk signaling involved in cancer cell survival: a newly emerging anticancer therapeutic target. Therapeutic Advances in Medical Oncology, Sep 2019. URL: https://doi.org/10.1177/1758835919875574, doi:10.1177/1758835919875574. This article has 47 citations and is from a peer-reviewed journal.

10. (park2019mkk7theessential pages 2-4): Jae Gwang Park, Nur Aziz, and Jae Youl Cho. Mkk7, the essential regulator of jnk signaling involved in cancer cell survival: a newly emerging anticancer therapeutic target. Therapeutic Advances in Medical Oncology, Sep 2019. URL: https://doi.org/10.1177/1758835919875574, doi:10.1177/1758835919875574. This article has 47 citations and is from a peer-reviewed journal.

11. (rana2013mixedlineagekinasecjun pages 2-3): A. Rana, B. Rana, Rajakishore Mishra, Gautam Sondarva, Velusamy Rangasamy, Subhasis Das, N. Viswakarma, and A. Kanthasamy. Mixed lineage kinase-c-jun n-terminal kinase axis: a potential therapeutic target in cancer. Genes &amp; Cancer, 4:334-341, Apr 2013. URL: https://doi.org/10.1177/1947601913485415, doi:10.1177/1947601913485415. This article has 42 citations.

12. (rattanasinchai2016mlk3signalingin pages 3-5): Chotirat Rattanasinchai and Kathleen Gallo. Mlk3 signaling in cancer invasion. Cancers, 8:51, May 2016. URL: https://doi.org/10.3390/cancers8050051, doi:10.3390/cancers8050051. This article has 53 citations and is from a peer-reviewed journal.

13. (cuevas2007roleofmitogenactivated pages 5-7): B. Cuevas, A. Abell, and G. Johnson. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene, 26:3159-3171, May 2007. URL: https://doi.org/10.1038/sj.onc.1210409, doi:10.1038/sj.onc.1210409. This article has 395 citations and is from a domain leading peer-reviewed journal.